The licensed technology, developed by ICMR-NICED [now ICMR- National Institute for Research in Bacterial Infections (NIRBI)], is a novel Salmonella Vaccine effective against Typhoid, Paratyphoid Fever, and Salmonella Typhimurium Gastroenteritis, representing a major leap toward addressing enteric disease burden.